文献速递白血病

DNA聚合酶θ保护白血病细胞免受代谢诱导的DNA损伤

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage.
PubMed 文献 · Blood · 2023-01-01

白血病细胞蓄积DNA损伤但DNA修复机制改变使其免于凋亡。本研究显示丝氨酸/一碳循环代谢产生的甲醛导致毒性DNA-蛋白质交联(DPC)蓄积,致癌性酪氨酸激酶(OTK)通过ERK1/2抑制c-CBL介导的POLθ泛素化降解而上调POLθ,POLθ介导的末端连接修复含DPC的双链断裂;遗传和药理靶向POLθ的聚合酶与解旋酶活性均有抗白血病作用,OTK抑制剂或依托泊苷可增强POLθ抑制剂疗效。

要点

  • OTK(FLT3-ITD、JAK2 V617F、BCR-ABL1)通过ERK1/2抑制c-CBL对POLθ的泛素化降解而上调POLθ。
  • POLθ介导的末端连接修复甲醛代谢产生的毒性DPC相关DNA双链断裂,保护白血病细胞。
  • 靶向POLθ聚合酶和解旋酶活性均有抗白血病效果,OTK抑制剂或依托泊苷可增强POLθ抑制剂疗效。

核心结论

  • POLθ在保护白血病细胞免受甲醛触发的代谢诱导毒性DNA损伤中起重要作用,可作为治疗靶点。

研究设计与样本

  • 研究采用白血病细胞、小鼠骨髓细胞及体内外模型,探讨POLθ在OTK阳性白血病细胞DNA损伤修复中的作用及靶向策略。

主要发现

  • 丝氨酸/一碳循环代谢产生的甲醛导致白血病细胞(尤其是携带OTK的驱动克隆)中毒性DPC蓄积。
  • OTK通过ERK1/2依赖性抑制c-CBL E3连接酶介导的POLθ泛素化及蛋白酶体降解,增强POLθ表达。
  • OTK阳性细胞中POLθ过表达通过POLθ介导的末端连接有效修复含DPC的DNA双链断裂。
  • 在Polq-/-小鼠骨髓细胞中,OTK及其他白血病诱导癌基因(尤其导致BRCA1/2同源重组抑制者,伴或不伴DNA-PK依赖性非同源末端连接抑制)的转化活性被消除。
  • 遗传和药理靶向POLθ聚合酶与解旋酶活性显示两者均为白血病细胞的潜在靶点;OTK抑制剂或DPC诱导药物依托泊苷在体外和体内增强POLθ抑制剂的抗白血病效果。

临床怎么用

  • 作者结论认为POLθ对保护白血病细胞免受甲醛触发的代谢诱导毒性DNA损伤至关重要,并可被靶向以实现治疗效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leukemia cells accumulate DNA damage, but altered DNA repair mechanisms protect them from apoptosis. We showed here that formaldehyde generated by serine/1-carbon cycle metabolism contributed to the accumulation of toxic DNA-protein crosslinks (DPCs) in leukemia cells, especially in driver clones harboring oncogenic tyrosine kinases (OTKs: FLT3(internal tandem duplication [ITD]), JAK2(V617F), BCR-ABL1). To counteract this effect, OTKs enhanced the expression of DNA polymerase theta (POLθ) via ERK1/2 serine/threonine kinase-dependent inhibition of c-CBL E3 ligase-mediated ubiquitination of POLθ and its proteasomal degradation. Overexpression of POLθ in OTK-positive cells resulted in the efficient repair of DPC-containing DNA double-strand breaks by POLθ-mediated end-joining. The transforming activities of OTKs and other leukemia-inducing oncogenes, especially of those causing the inhibition of BRCA1/2-mediated homologous recombination with and without concomitant inhibition of DNA-PK-dependent nonhomologous end-joining, was abrogated in Polq-/- murine bone marrow cells. Genetic and pharmacological targeting of POLθ polymerase and helicase activities revealed that both activities are promising targets in leukemia cells. Moreover, OTK inhibitors or DPC-inducing drug etoposide enhanced the antileukemia effect of POLθ inhibitor in vitro and in vivo. In conclusion, we demonstrated that POLθ plays an essential role in protecting leukemia cells from metabolically induced toxic DNA lesions triggered by formaldehyde, and it can be targeted to achieve a therapeutic effect.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Vekariya U, Toma M, Nieborowska-Skorska M, et al. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage. Blood. 2023. PMID: 36580665. doi:10.1182/blood.2022018428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。